H Henry Li1, Dumitru Moldovan2, Jonathan A Bernstein3, Avner Reshef4, Gregor Porebski5, Marcin Stobiecki5, James Baker6, Robyn Levy7, Anurag Relan8, Marc Riedl9. 1. Institute for Asthma and Allergy, P.C., Chevy Chase, Md. Electronic address: hl@allergyasthma.us. 2. University of Medicine and Pharmacy, Tirgu Mures, Romania. 3. University of Cincinnati, Cincinnati, Ohio. 4. Tel Aviv University, Sheba Medical Center, Tel-Hashomer, Israel. 5. Faculty of Medicine, Department of Clinical and Environmental Allergology, Jagiellonian University, Krakow, Poland. 6. Baker Allergy Asthma Dermatology, Lake Oswego, Ore. 7. Family Allergy & Asthma Center, Atlanta, Ga. 8. Pharming Technologies BV, Leiden, The Netherlands. 9. UCSD School of Medicine, La Jolla, Calif.
Abstract
BACKGROUND: Hereditary angioedema (HAE) caused by a deficiency in functional C1 esterase inhibitor (C1INH) is characterized by recurrent episodes of cutaneous and/or mucosal/submucosal tissue swelling affecting multiple anatomic locations. Previous studies demonstrated efficacy of recombinant human C1INH (rhC1INH) for acute HAE attacks. OBJECTIVE: This study evaluated the efficacy and safety of rhC1INH (50 IU/kg) for the treatment of multiple HAE attacks in an open-label extension study. METHODS:Time to onset of symptom relief and time to minimal symptoms were assessed using a Treatment Effect Questionnaire (TEQ), a visual analog scale, and a 6-point ordinal scale Investigator Score. RESULTS: Forty-four patients received rhC1INH, and a single dose was administered for 215 of 224 (96%) attacks. Median time to beginning of symptom relief based on TEQ for the first 5 attacks was 75.0 (95% CI, 69-89) minutes, ranging from 62.5 (95% CI, 48-90) to 134.0 (95% CI, 32-119) minutes. Median time to minimal symptoms using TEQ for the first 3 attacks was 303.0 (95% CI, 211-367) minutes. rhC1INH was well tolerated. There were no discontinuations due to adverse events. No thrombotic or anaphylactic events were reported, and repeat rhC1INH treatments were not associated with neutralizing anti-C1INH antibodies. CONCLUSIONS: A single 50-IU/kg dose rhC1INH was effective for improving symptoms of an HAE attack with sustained efficacy for treatment of subsequent attacks. rhC1INH had a positive safety profile throughout the study. This study supports repeated use of rhC1INH over time in patients with HAE attacks.
RCT Entities:
BACKGROUND: Hereditary angioedema (HAE) caused by a deficiency in functional C1 esterase inhibitor (C1INH) is characterized by recurrent episodes of cutaneous and/or mucosal/submucosal tissue swelling affecting multiple anatomic locations. Previous studies demonstrated efficacy of recombinant humanC1INH (rhC1INH) for acute HAE attacks. OBJECTIVE: This study evaluated the efficacy and safety of rhC1INH (50 IU/kg) for the treatment of multiple HAE attacks in an open-label extension study. METHODS: Time to onset of symptom relief and time to minimal symptoms were assessed using a Treatment Effect Questionnaire (TEQ), a visual analog scale, and a 6-point ordinal scale Investigator Score. RESULTS: Forty-four patients received rhC1INH, and a single dose was administered for 215 of 224 (96%) attacks. Median time to beginning of symptom relief based on TEQ for the first 5 attacks was 75.0 (95% CI, 69-89) minutes, ranging from 62.5 (95% CI, 48-90) to 134.0 (95% CI, 32-119) minutes. Median time to minimal symptoms using TEQ for the first 3 attacks was 303.0 (95% CI, 211-367) minutes. rhC1INH was well tolerated. There were no discontinuations due to adverse events. No thrombotic or anaphylactic events were reported, and repeat rhC1INH treatments were not associated with neutralizing anti-C1INH antibodies. CONCLUSIONS: A single 50-IU/kg dose rhC1INH was effective for improving symptoms of an HAE attack with sustained efficacy for treatment of subsequent attacks. rhC1INH had a positive safety profile throughout the study. This study supports repeated use of rhC1INH over time in patients with HAE attacks.
Authors: Lakshmi C Wijeyewickrema; Emilie Lameignere; Lilian Hor; Renee C Duncan; Toshikazu Shiba; Richard J Travers; Piyushkumar R Kapopara; Victor Lei; Stephanie A Smith; Hugh Kim; James H Morrissey; Robert N Pike; Edward M Conway Journal: Blood Date: 2016-06-23 Impact factor: 22.113
Authors: Matteo Ferrando; Diego Bagnasco; Gilda Varricchi; Stefano Bernardi; Alice Bragantini; Giovanni Passalacqua; Giorgio Walter Canonica Journal: Allergy Asthma Immunol Res Date: 2017-01 Impact factor: 5.764
Authors: Anna Valerieva; Maria T Staevska; Vesna Grivcheva-Panovska; Milos Jesenak; Kinga Viktória Kőhalmi; Katarina Hrubiskova; Andrea Zanichelli; Luca Bellizzi; Anurag Relan; Roman Hakl; Henriette Farkas Journal: World Allergy Organ J Date: 2021-04-22 Impact factor: 4.084
Authors: Douglas H Jones; Priya Bansal; Jonathan A Bernstein; Shahnaz Fatteh; Joseph Harper; F Ida Hsu; Maeve O'Connor; Nami Park; Daniel Suez Journal: World Allergy Organ J Date: 2022-01-27 Impact factor: 4.084
Authors: H Farkas; I Martinez-Saguer; K Bork; T Bowen; T Craig; M Frank; A E Germenis; A S Grumach; A Luczay; L Varga; A Zanichelli Journal: Allergy Date: 2016-09-08 Impact factor: 13.146